Akoya Biosciences Stock Today
| AKYA Stock | USD 1.68 0.06 3.70% |
PerformanceVery Weak
| Odds Of DistressAbout Average
|
Akoya Biosciences is trading at 1.68 as of the 20th of March 2025, a 3.70 percent increase since the beginning of the trading day. The stock's open price was 1.62. Akoya Biosciences has 48 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 16th of April 2021 | Category Healthcare | Classification Health Care |
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts. The company has 49.57 M outstanding shares of which 3.25 M shares are presently shorted by private and institutional investors with about 9.67 trading days to cover. More on Akoya Biosciences
Moving against Akoya Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Akoya Stock Highlights
| CEO President | Brian McKelligon | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAkoya Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Akoya Biosciences' financial leverage. It provides some insight into what part of Akoya Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Akoya Biosciences (AKYA) is traded on NASDAQ Exchange in USA. It is located in 100 Campus Drive, Marlborough, MA, United States, 01752 and employs 330 people. Akoya Biosciences is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 80.31 M. Akoya Biosciences conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 49.57 M outstanding shares of which 3.25 M shares are presently shorted by private and institutional investors with about 9.67 trading days to cover.
Akoya Biosciences currently holds about 87.61 M in cash with (44.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Akoya Biosciences Probability Of Bankruptcy
Ownership AllocationAkoya Biosciences holds a total of 49.57 Million outstanding shares. Akoya Biosciences shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 67.21 percent of Akoya Biosciences outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Also note that nearly eighteen million three hundred fourty-six thousand eight hundred fifty-six invesors are currently shorting Akoya Biosciences expressing very little confidence in its future performance.
Check Akoya Ownership Details
Akoya Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Osterweis Capital Management Inc | 2024-12-31 | 126.1 K | |
| Schonfeld Strategic Advisors Llc | 2024-12-31 | 122 K | |
| Bridgeway Capital Management, Llc | 2024-12-31 | 105.6 K | |
| Ubs Group Ag | 2024-12-31 | 85.2 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 80.3 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 63 K | |
| Deutsche Bank Ag | 2024-12-31 | 54.8 K | |
| Bank Of New York Mellon Corp | 2024-12-31 | 50.7 K | |
| Citigroup Inc | 2024-12-31 | 48.8 K | |
| Blue Water Life Science Advisors, Llc | 2024-12-31 | 4.7 M | |
| Blackrock Inc | 2024-12-31 | 1.6 M |
Akoya Biosciences Historical Income Statement
Akoya Stock Against Markets
Akoya Biosciences Corporate Management
| Clifford Hoyt | VP Affairs | Profile | |
| Marilee MBA | Chief Officer | Profile | |
| Jennifer Kamocsay | General Counsel | Profile | |
| Nikolay Samusik | CoFounder | Profile | |
| Anthony Catalano | Senior Operations | Profile |
Already Invested in Akoya Biosciences?
The danger of trading Akoya Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Akoya Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Akoya Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Akoya Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Akoya Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akoya Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akoya Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akoya Biosciences Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akoya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akoya Biosciences. If investors know Akoya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akoya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share | Quarterly Revenue Growth (0.19) | Return On Assets | Return On Equity |
The market value of Akoya Biosciences is measured differently than its book value, which is the value of Akoya that is recorded on the company's balance sheet. Investors also form their own opinion of Akoya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Akoya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akoya Biosciences' market value can be influenced by many factors that don't directly affect Akoya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akoya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akoya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akoya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.